A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer (CELLO-1)
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Epizyme, Inc.
Terminated
The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.
Other terminated trials from Epizyme, Inc.
- T-cell Lymphoma · Mar 2026
- Advanced Malignant Solid Tumor · Mar 2025
- Advanced Epithelioid Sarcoma · Phase PHASE1 · Jun 2024
- Diffuse Large B Cell Lymphoma Refractory · Phase PHASE1 · Apr 2024
- Head and Neck Squamous Cell Carcinoma · Phase PHASE1 · Feb 2024
More terminations from Epizyme, Inc.
Other Metastatic Castration-resistant Prostate Cancer trials with similar outcome
- NCT04629781 · Phase PHASE1 · Jan 2024
- NCT04631601 · Phase PHASE1/PHASE2 · Oct 2023
- NCT05177770 · Phase PHASE2 · Apr 2023
- NCT02744287 · Phase PHASE1 · Mar 2023
- NCT04227275 · Phase PHASE1 · Nov 2022
Browse all Metastatic Castration-resistant Prostate Cancer trials
This PHASE1/PHASE2 trial investigates Metastatic Castration-resistant Prostate Cancer and Metastatic Prostate Cancer and is currently terminated or withdrawn. Epizyme, Inc. leads this study, which shows 27 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
27 versions recorded-
Mar 2026 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Terminated PHASE1/PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 22 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2022 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Epizyme, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .